Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B5RO
|
|||
| Former ID |
DIB008449
|
|||
| Drug Name |
REN-1654
|
|||
| Synonyms |
Antineurodegeneratives, Centaur; CPI-1160; CPI-1189; Parkinsons therapy, Centaur; REN-1189
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7] | Phase 2 | [1] | |
| Company |
Centaur Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H18N2O2
|
|||
| Canonical SMILES |
CC(=O)NC1=CC=C(C=C1)C(=O)NC(C)(C)C
|
|||
| InChI |
1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)
|
|||
| InChIKey |
DJKNRCWSXSZACF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 183619-38-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | JNK signaling pathway (JNK pathway) | Target Info | Modulator | [2] |
| MAPK/ERK signaling pathway (MAPK pathway) | Target Info | Modulator | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00107055) Study of REN-1654 in Patients With Sciatica Pain. U.S. National Institutes of Health. | |||
| REF 2 | US patent application no. 2006,0270,742, Compositions and methods for the treatment of neurodegenerative diseases. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.